Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
Phase Ib/IIa Study of an Anti-Epidermal Growth Factor Receptor (EGFr) Antibody Cetuximab in Combination With Carboplatin-Paclitaxel in Patients With Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer
Sponsor: Eli Lilly and Company
Listed as NCT00034541, this PHASE1/PHASE2 trial focuses on Carcinoma, Non-Small-Cell Lung and remains completed. Sponsored by Eli Lilly and Company, it has been updated 8 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Aug 2018 — Nov 2019 [monthly]
Completed PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Dec 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
- Greenwich Hospital
- Indiana University
- University of Colorado, Denver
For direct contact, visit the study record on ClinicalTrials.gov .